CTS Corp SEC Filings

CTS Corp (CTS) reported a director equity grant. On 11/06/2025, a director acquired 3,500 shares of common stock at $0 (code A), reported as a grant of restricted stock units.

The filing notes these RSUs vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date. After the transaction, the reporting person beneficially owns 12,200 shares, held directly.

CTS Corp (CTS) director Robert Profusek reported acquiring 3,500 shares of common stock on 11/06/2025 at $0. The award reflects restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director.

Following the transaction, Profusek beneficially owns 101,742 shares directly and 1,800 shares indirectly through a spouse. The filing was made by one reporting person.

CTS Corp reported an initial statement of beneficial ownership by a director. The filing lists 3,500 common shares held directly as of 11/06/2025. The footnote states that certain restricted stock units vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.

CTS Corporation (CTS)11/06/2025, a director acquired 3,500 shares at $0, reported as a grant tied to restricted stock units. The filing notes these RSUs vest 100% on the first anniversary of the grant date, contingent on continued service as a director through the vesting date.

Following the transaction, the reporting person beneficially owns 46,700 shares, held directly. No derivative securities were listed.

CTS Corporation (CTS) disclosed a Form 4 for director Amy M. Dodrill. On 11/06/2025, she acquired 3,500 shares of common stock at $0, reported as a grant of restricted stock units that vest 100% on the first anniversary of the grant date, contingent on continued service as a director. After this transaction, her beneficial ownership stands at 8,800 shares, held directly.

CTS Corp (CTS) director Donna Costello reported an equity award on a Form 4. On 11/06/2025, she acquired 3,500 shares of common stock at $0 (code A). Following the transaction, her beneficial ownership stands at 19,500 shares, held directly.

The filing notes these were restricted stock units that vest 100% on the first anniversary of the grant date, contingent on her continued service as a director through the vesting date.

CTS Corporation expanded its Board of Directors from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services and will join CTS’s Nominating, Governance and Sustainability Committee and Technology and Transactions Committee.

As a non-employee director, she will receive compensation consistent with other non-employee directors as described in the Company’s March 28, 2025 proxy statement. The Company reported no arrangements leading to her selection and no related person transactions requiring disclosure under Item 404(a). CTS will enter into its standard indemnification agreement with her, and a related press release was furnished as Exhibit 99.1 on November 6, 2025.

CTS Corporation (NYSE: CTS) reported Q3 2025 results. Net sales were $142.97M, up from $132.38M a year ago, driven by Industrial ($37.10M vs $30.75M), Medical ($21.96M vs $18.02M), and Aerospace & Defense ($25.36M vs $20.59M), while Transportation softened ($58.55M vs $63.03M). Operating earnings were essentially flat at $20.94M. Net earnings were $13.69M vs $18.08M, with diluted EPS of $0.46 vs $0.59 as higher SG&A and R&D offset gross profit gains.

Year to date, sales reached $404.05M vs $388.30M and net earnings were $45.58M vs $43.91M (diluted EPS $1.52 vs $1.43). Cash provided by operations was $72.89M, ending cash was $110.30M, and long‑term debt was $90.70M (weighted average rate 5.56%). The company repurchased 399,500 shares for $16.74M in Q3 and $40.08M year to date, with approximately $21.34M remaining under its program. Remediation reserves increased to $15.90M; for the Asheville, NC matter, the company recorded a $5.97M loss estimate within an updated exposure range of $5.97M to $8.29M. Shares outstanding were 29,052,423 as of October 21, 2025.

CTS Corporation furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8‑K. The presentation, included as Exhibit 99.1 and dated October 2025, may be used in meetings with investors and analysts during the fiscal year ended December 31, 2025. The company states the materials are furnished, not filed, and are not subject to Section 18 liability or incorporated by reference unless specifically referenced.